Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol.
Low levels of high-density lipoprotein cholesterol (HDL-C) constitute a strong risk factor for developing coronary heart disease. This risk can be decreased by even slight improvements in HDL-C levels. This review discusses both pharmacologic and nonpharmacologic treatments of patients with low levels of HDL-C, including lifestyle modifications and the benefits of oral estrogens, niacin, fibrates, statins, and combination drug therapy.
Bowen
P H
PH
Department of Medicine, Duke University Medical Center, Box 3510, Durham, NC 27710, USA.
Guyton
J R
JR
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood*; D003327:Coronary Disease / Q000517:prevention & control; D004967:Estrogens / Q000627:therapeutic use; D015444:Exercise; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008019:Life Style; D009525:Niacin / Q000627:therapeutic use; D012307:Risk Factors
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D004967:Estrogens; D000960:Hypolipidemic Agents; D009525:Niacin